Australia: Application to list on PBS does not constitute patent infringement per se

The Federal Court has recently considered when an offer to supply during the term of a patent constitutes patent infringement. The Court has held that lodging an application for PBS listing is not an offer to supply and does not constitute patent infringement per se.

The Federal Court in Apotex Pty Ltd v Warner-Lambert Company LLC (No 3) [2017] FCA 94 has confirmed that lodging an application for listing on the Pharmaceutical Benefits Scheme (PBS) does not constitute exploitation of a patent and therefore does not amount to patent infringement. However, offers made during the term of a patent to supply infringing products after patent expiry do constitute exploitation of a patent and amount to patent infringement.

The decision has implications for both innovator and generic pharmaceutical companies regarding the preventative and preparatory steps, respectively, that may be taken in the lead-up to patent expiry.

Form of final injunctive relief for patent infringement

The decision concerned the form of injunctive relief that Pfizer was entitled to, given the conclusion of two separate proceedings between Apotex Pty Ltd and Warner-Lambert Company LLC and related entities (together, Pfizer) on one hand, and Pfizer and Generic Partners Pty Ltd on the other, in which the relevant claims of Pfizer's patent for methods of use of the drug pregabalin were held to be valid and infringed by both Apotex and Generic Partners.

Questions considered by the Federal Court

The issue before the Court was whether an application for listing on the PBS by Apotex would amount to infringement of the relevant claims of Pfizer's patent and whether Apotex should therefore be restrained from making such an application prior to expiry of Pfizer's patent. In determining this issue, the Court addressed the following questions:

  1. Does an offer made during the term of a patent to supply infringing products after patent expiry constitute an offer to supply within the definition of "exploit" in the Patents Act 1990 and therefore infringe the patent?
  2. Does making an application for PBS listing constitute an offer to supply or otherwise dispose of infringing products and therefore amount to an act of patent infringement?

Offer to supply after patent expiry made during patent term is an act of infringement

Justice Nicholas held that an offer to supply after patent expiry made during the patent term is one of the exclusive rights to "exploit" the invention given to the patentee under section 13 of the Patents Act. When a person offers a patented product for sale during the term of the patent without the patentee's consent, that person infringes the patent even if no actual sale or delivery of the product occurs before patent expiry.

Justice Nicholas held that whether there has been an "offer" under the Patents Act is broader than the narrow meaning given to the word in contract law and encompasses an expression of a willingness to sell. However, not every expression of a willingness to sell will constitute an "offer" within the statutory definition. For example, it would not constitute an "offer" if a supplier, acting in good faith, merely states that it proposes to offer a product as soon as the relevant patent expires.

Application for PBS listing not an act of infringement

Justice Nicholas then considered whether making an application for PBS listing before patent expiry constitutes the making of an offer to supply during the term of the patent and therefore would infringe Pfizer's patent. Justice Nicholas held that it would not.

By applying for PBS listing, Apotex proposed to engage with the relevant statutory scheme so that it could offer its pregabalin products for sale at subsidised prices once Pfizer's patent had expired. Such steps would fall short of offering to sell or otherwise dispose of the products within the definition of "exploit" in the Patents Act. In coming to this conclusion, Justice Nicholas assumed that Apotex would expressly or impliedly represent to the Minister for Health that it would only make the products available for supply during the guaranteed period upon the Minister making a determination of a brand of a pharmaceutical item under section 85(6) of the National Health Act 1953. This suggests that that an application for PBS listing will only constitute an offer to supply once a determination of a brand has been made by the Minister under section 85(6) of the National Health Act 1953.

Justice Nicholas also held that applying for PBS listing does not otherwise constitute an act of exploitation of the invention. He characterised the making of an application for PBS listing as a mere preparatory step to enable the exploitation of the invention at a later point in time.

He therefore made final injunctive orders in a form which do not prevent Apotex or Generic Partners from taking steps to obtain PBS listing of their pregabalin products. However, an order was made requiring Apotex/Generic Partners to notify the Australian Government Department of Health of the granting of the permanent injunction and its terms.

Does an application for PBS listing provide grounds for seeking interlocutory injunctive relief?

While Justice Nicholas held making an application for PBS listing was not of itself an act of infringement, he was clear in his reasons that making such an application may justify the grant of interlocutory injunctive relief to restrain threatened acts of infringement, for example, restraining the making of a PBS listing application until the determination of the proceeding because of the risk that PBS listing of a product would trigger statutory price reductions and price review mechanisms that may cause harm to the patentee's or exclusive licensee's business. However, the Court was here concerned with the form of final relief.

Implications of the Apotex decision

Parties who are intending to bring patented products to market post-patent expiry, including generic pharmaceutical companies, need to consider carefully whether their conduct may be construed as an offer to supply made during the term of the patent, without the consent of the patentee, and therefore constitute patent infringement. Such conduct includes representations and arrangements that may be entered into. A careful review of any such conduct would be prudent.

Innovator pharmaceutical companies should also be aware that this decision will limit their ability to prevent generic pharmaceutical companies from applying for PBS listing of their products where the listing will take place post-patent expiry. However, the decision does not prevent a patentee from relying on a PBS listing application as a basis for seeking interlocutory injunctive relief to restrain threatened acts of infringement, where the balance of convenience favours the granting of such relief.

This decision has been appealed by Pfizer and Apotex has cross-appealed. The grounds of appeal are unclear at this stage, but it is likely that the conclusions reached by Justice Nicholas regarding what constitutes an offer to supply and therefore patent infringement will be re-considered.

RELATED KNOWLEDGE

Clayton Utz communications are intended to provide commentary and general information. They should not be relied upon as legal advice. Formal legal advice should be sought in particular transactions or on matters of interest arising from this bulletin. Persons listed may not be admitted in all states and territories.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.